Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway — Hussein Kadhem Al‐Hakeim (2023) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway
Shared by
Michael Maes
University of Electronic Science and Technology of China
Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway
Letter
2023
en
Authors
+2 more
HA
Hussein Kadhem Al‐Hakeim
AA
Anwar Khairi Abed
AA
Abbas F. Almulla
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Preprint
2023
Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway
Hussein Kadhem Al‐Hakeim
,
Anwar Khairi Abed
,
Abbas F. Almulla
,
Shatha Rouf Moustafa
,
Michael Maes
Article
2016
Body image dissatisfaction in pregnant and non-pregnant females is strongly predicted by immune activation and mucosa-derived activation of the tryptophan catabolite (TRYCAT) pathway
Chutima Roomruangwong
,
Buranee Kanchanatawan
,
André F. Carvalho
,
Sunee Sirivichayakul
,
S. Duleu
,
M. Geffard
,
Michael Maes
Article
2017
Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs
Buranee Kanchanatawan
,
Sunee Sirivichayakul
,
André F. Carvalho
,
George Anderson
,
Piotr Gałecki
,
Michael Maes
Article
2012
Schizophrenia: Linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression
George Anderson
,
Michael Maes
Article
2024
The tryptophan catabolite or kynurenine pathway in Long COVID disease: A systematic review and meta-analysis
Abbas F. Almulla
,
Yanin Thipakorn
,
Bo Zhou
,
Aristo Vojdani
,
Rossitsa Paunova
,
Michael Maes
Discussion(0)
No comments yet. Be the first to comment.